Top

Published in:

01-08-2017 | Original Article

Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences

Authors: Ennio Giulio Favalli, Irene Pontikaki, Andrea Becciolini, Martina Biggioggero, Nicola Ughi, Micol Romano, Chiara Crotti, Maurizio Gattinara, Valeria Gerloni, Antonio Marchesoni, Pier Luigi Meroni

Published in: Clinical Rheumatology | Issue 8/2017

Abstract

The aim of this study is to retrospectively analyze 10-year drug survival of first-line TNF inhibitor (TNFi) in rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), and juvenile idiopathic arthritis (JIA) patients, comparing withdrawal rates and discontinuation pattern between adult- and juvenile-onset populations. RA, AS, PsA, and JIA patients treated with infliximab, etanercept, or adalimumab as first TNFi between 1999 and 2015 were extracted from a local registry. Drug survival up to 10-year follow-up was evaluated by the Kaplan-Meier method and compared according to age (adult vs juvenile onset), TNFi agent, and discontinuation reason by a stratified log-rank test. Three hundred sixty JIA (205 etanercept, 66 adalimumab, and 89 infliximab) and 951 (607 RA, 188 AS, and 156 PsA) adult patients (464 infliximab, 262 adalimumab, and 225 etanercept) were included. After exclusion of systemic-onset JIA (18.5%), overall 10-year retention rate was 31.8%, with no difference between adult- and juvenile-onset patients (32.1 and 30.2%, respectively; HR 0.938 [95% CI 0.782–1.125]). Etanercept showed the highest drug survival in adult-onset population (p < 0.0001 vs both monoclonal antibodies) and infliximab the lowest in juvenile-onset population (p = 0.005 vs adalimumab and p < 0.0001 vs etanercept). Inefficacy was the most frequent reason for TNFi withdrawal in adult population (29.75%) with a significantly higher risk of discontinuation than in juvenile-onset subgroup (HR 1.390 [95% CI 1.060–1.824]). Serious infections and malignancies caused TNFi withdrawal only in adult whereas gastrointestinal, neuropsychiatric, and ocular complications quite only in juvenile patients. Despite a similar 10-year drug survival, adult- and juvenile-onset subpopulations showed a significantly different pattern of TNFi reasons for discontinuation.

Petty RE, Southwood TR, Manners P et al (2004) International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 31:390–392PubMed

Ruperto N, Lovell DJ, Cuttica R et al (2010) Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension. Ann Rheum dis 69:718–722CrossRefPubMed

Gerloni V, Pontikaki I, Gattinara M et al (2005) Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor alpha monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis: results of an open-label prospective study. Arthritis Rheum 52:548–553CrossRefPubMed

Marchesoni A, Zaccara E, Gorla R et al (2009) TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann N Y Acad Sci 1173:837–846CrossRefPubMed

Glintborg B, Østergaard M, Dreyer L et al (2011) Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor α therapy: results from the nationwide Danish DANBIO registry. Arthritis Rheum 63:382–390CrossRefPubMed

Glintborg B, Østergaard M, Krogh NS et al (2010) Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years’ surveillance in the Danish nationwide DANBIO registry. Ann Rheum dis 69:2002–2008CrossRefPubMed

Lie E, Kristensen LE, Forsblad-d’Elia H et al (2015) The effect of comedication with conventional synthetic disease modifying antirheumatic drugs on TNF inhibitor drug survival in patients with ankylosing spondylitis and undifferentiated spondyloarthritis: results from a nationwide prospective study. Ann Rheum dis 74:970–978CrossRefPubMed

Fagerli KM, Lie E, van der Heijde DM et al (2014) The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study. Ann Rheum dis 73:132–137CrossRefPubMed

Favalli EG, Pregnolato F, Biggioggero M et al (2016) Twelve-year retention rate of first-line tumor necrosis factor inhibitors in rheumatoid arthritis: real-life data from a local registry. Arthritis Care & Research 68:432–439CrossRef

10.

Tynjala P, Vahasalo P, Honkanen V et al (2009) Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis. Ann Rheum dis 68:552–557CrossRefPubMed

11.

Mourão AF, Santos MJ, Melo Gomes JA et al (2016) Effectiveness and long-term retention of anti-tumour necrosis factor treatment in juvenile and adult patients with juvenile idiopathic arthritis: data from Reuma.pt. Rheumatology (Oxford) 55:697–703CrossRef

12.

Arnett FC, Edworthy SM, Bloch DA et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324CrossRefPubMed

13.

Linden SVD, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. Arthritis Rheum 27:361–368CrossRefPubMed

14.

Moll JM, Wright V (1973) Psoriatic arthritis. Semin Arthritis Rheum 3:55–78CrossRefPubMed

15.

Lin Y-T, Wang C-T, Gershwin ME et al (2011) The pathogenesis of oligoarticular/polyarticular vs systemic juvenile idiopathic arthritis. Autoimmun rev 10:482–489CrossRefPubMed

16.

Vastert SJ, Kuis W, Grom AA (2009) Systemic JIA: new developments in the understanding of the pathophysiology and therapy. Best Pract res Clin Rheumatol 23:655–664CrossRefPubMedPubMedCentral

17.

Favalli EG, Selmi C, Becciolini A, et al. Eight-year retention rate of first-line tumor necrosis factor inhibitors in spondyloarthritis: a multi-center retrospective analysis. Arthritis Care Res 2016; Accepted Author Manuscript. doi:10.1002/acr.23090

18.

Soliman MM, Ashcroft DM, Watson KD et al (2011) Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Ann Rheum dis 70:583–589CrossRefPubMedPubMedCentral

19.

Carmona L, Gomez-Reino JJ, BIOBADASER Group (2006) Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. Arthritis Res Ther 8:R72CrossRefPubMedPubMedCentral

20.

Pan Du SM, Dehler S, Ciurea A et al (2009) Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum 61:560–568CrossRef

21.

Kievit W, Fransen J, Adang EMM et al (2011) Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register. Rheumatology (Oxford) 50:196–203CrossRef

22.

Rosenblat JD, Cha DS, Mansur RB et al (2014) Inflamed moods: a review of the interactions between inflammation and mood disorders. Prog Neuro-Psychopharmacol Biol Psychiatry 53:23–34CrossRef

23.

Gerloni V, Pontikaki I, Gattinara M et al (2008) Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients. Ann Rheum dis 67:1145–1152CrossRefPubMed

24.

Sen ES, Dick AD, Ramanan AV (2015) Uveitis associated with juvenile idiopathic arthritis. Nat rev Rheumatol 11:338–348CrossRefPubMed

25.

Barthel D, Ganser G, Kuester R-M et al (2015) Inflammatory bowel disease in juvenile idiopathic arthritis patients treated with biologics. J Rheumatol 42:2160–2165CrossRefPubMed

26.

Stolwijk C, van Tubergen A, Castillo-Ortiz JD et al (2015) Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis. Ann Rheum dis 74:65–73CrossRefPubMed

27.

Tappeiner C, Schenck S, Niewerth M et al (2016) Impact of antiinflammatory treatment on the onset of uveitis in juvenile idiopathic arthritis: longitudinal analysis from a nationwide pediatric rheumatology database. Arthritis Care & Research 68:46–54CrossRef

28.

Wu D, Guo Y-Y, Xu N-N et al (2015) Efficacy of anti-tumor necrosis factor therapy for extra-articular manifestations in patients with ankylosing spondylitis: a meta-analysis. BMC Musculoskelet Disord 16:19CrossRefPubMedPubMedCentral

29.

Simonini G, Druce K, Cimaz R et al (2014) Current evidence of anti-tumor necrosis factor α treatment efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach of individual drugs. Arthritis Care & Research 66:1073–1084CrossRef

30.

Braun J, Baraliakos X, Listing J et al (2005) Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 52:2447–2451CrossRefPubMed

31.

Sandborn WJ (2003) Optimizing anti-tumor necrosis factor strategies in inflammatory bowel disease. Curr Gastroenterol rep 5:501–505CrossRefPubMed

32.

Braun J, Baraliakos X, Listing J et al (2007) Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum 57:639–647CrossRefPubMed

33.

Beukelman T, Xie F, Chen L et al (2012) Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum 64:2773–2780CrossRefPubMedPubMedCentral

34.

Doran MF, Crowson CS, Pond GR et al (2002) Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 46:2287–2293CrossRefPubMed

35.

Listing J, Strangfeld A, Kary S et al (2005) Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 52:3403–3412CrossRefPubMed

36.

Greenberg JD, Reed G, Kremer JM et al (2010) Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. Ann Rheum dis 69:380–386CrossRefPubMed

37.

Galloway JB, Hyrich KL, Mercer LK et al (2011) Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) 50:124–131CrossRef

38.

Becker I, Horneff G. Risk of serious infection in juvenile idiopathic arthritis patients associated with TNF-inhibitors and disease activity in the German BIKER registry. Arthritis care & research Published Online First: 7 July 2016.

39.

Baecklund E, Iliadou A, Askling J et al (2006) Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 54:692–701CrossRefPubMed

40.

Nordstrom BL, Mines D, Gu Y et al (2012) Risk of malignancy in children with juvenile idiopathic arthritis not treated with biologic agents. Arthritis Care & Research 64:1357–1364CrossRef

41.

Hellgren K, Smedby KE, Backlin C et al (2014) Ankylosing spondylitis, psoriatic arthritis, and risk of malignant lymphoma: a cohort study based on nationwide prospectively recorded data from Sweden. Arthritis Rheumatol 66:1282–1290CrossRefPubMed

42.

Onel KB, Onel K (2012) Tumor necrosis factor inhibitors and cancer in juvenile idiopathic arthritis: disentangling the web. Arthritis Rheum 64:966–969CrossRefPubMed

43.

Bongartz T, Sutton AJ, Sweeting MJ et al (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. Jama 295:2275–2285CrossRefPubMed

44.

Strangfeld A, Hierse F, Rau R et al (2010) Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis res Ther 12:R5CrossRefPubMedPubMedCentral

45.

Mercer LK, Lunt M, Low ALS, Dixon WG, Watson KD, Symmons DPM et al (2015) Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum dis 74(6):1087–1093CrossRefPubMed

46.

Beukelman T, Haynes K, Curtis JR et al (2012) Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum 64:1263–1271CrossRefPubMedPubMedCentral

47.

Tanaka Y, Hirata S, Saleem B, Emery P (2013) Discontinuation of biologics in patients with rheumatoid arthritis. Clin Exp Rheumatol 31(4 Suppl 78):S22–S27PubMed

48.

Chang CY, Meyer RML, Reiff AO (2015) Impact of medication withdrawal method on flare-free survival in patients with juvenile idiopathic arthritis on combination therapy. Arthritis Care res 67(5):658–666CrossRef

49.

Hetland ML, Christensen IJ, Tarp U et al (2010) Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 62:22–32CrossRefPubMed

50.

Iannone F, Gremese E, Atzeni F et al (2012) Longterm retention of tumor necrosis factor-α inhibitor therapy in a large italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors. J Rheumatol 39:1179–1184. doi:10.3899/jrheum.111125 CrossRefPubMed

51.

Schaeverbeke T, Truchetet M-E, Kostine M, Barnetche T, Bannwarth B, Richez C (2016) Immunogenicity of biologic agents in rheumatoid arthritis patients: lessons for clinical practice. Rheumatology (Oxford) 55(2):210–220CrossRef

Title: Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences
Authors: Ennio Giulio Favalli
Irene Pontikaki
Andrea Becciolini
Martina Biggioggero
Nicola Ughi
Micol Romano
Chiara Crotti
Maurizio Gattinara
Valeria Gerloni
Antonio Marchesoni
Pier Luigi Meroni
Publication date: 01-08-2017
Publisher: Springer London
Published in: Clinical Rheumatology / Issue 8/2017
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-017-3712-8

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2017

Evaluating the cost-effectiveness of biologic treatments for psoriatic arthritis: can we make better use of patient data registries?

Standardizing and personalizing the treat to target (T2T) approach for rheumatoid arthritis using the Patient-Reported Outcomes Measurement Information System (PROMIS): baseline findings on patient-centered treatment priorities

Correlation of serum MMP3 and other biomarkers with clinical outcomes in patients with ankylosing spondylitis: a pilot study

Tumor necrosis factor-α -308 A/G gene polymorphism in children with juvenile idiopathic arthritis: relation to disease activity, damage, and functional status

Evaluation of the effect of Elaeagnus angustifolia alone and combined with Boswellia thurifera compared with ibuprofen in patients with knee osteoarthritis: a randomized double-blind controlled clinical trial

What do people search online concerning the “elusive” fibromyalgia? Insights from a qualitative and quantitative analysis of Google Trends

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page